Hereditary Retinal Diseases Introduction and Update

Hereditary Retinal Diseases Introduction and Update

Hereditary Retinal Diseases Introduction and update !"#"$%&'()*+(),-./&01& 2)3,%&'4)+"%#"565&.7&8"+("9%,& 8"+("9%,&'6%6)&:,"*);5"6$&<.##)9)&.7&=>?%,&8)@"+",)&& A55"56%,6&B;.7)55.;&",&6()&'>;9);$&0)4%;6?),6& & Objectives • 2)*")C&56>@$&6..#5&7.;&();)@"6%;$&;)3,%#&@"5)%5)5& • 2)*")C&"?"6%6.;5&.7&A280& • 2)*")C&4.6),3%#&6;)%6?),6&7.;&();)@"6%;$&;)3,%#&@"5)%5)5& Inherited retinal diseases • <.?4;"5)&%&C"@)&;%,9)&.7&9),)3+%##$&%,@&4(),.6$4"+%##$& ()6);.9),).>5&@"5)%5)5&6(%6&5(%;)&",&+.??.,&4;.9;)55"*)&#.55&.7& 4(.6.;)+)46.;&7>,+3.,&%++.?4%,")@&D$&*"5>%#&#.55E& • 8%$&.++>;&",&"5.#%3.,&.;&%5&4%;6&.7&%&?>#3F5$56)?"+&+.,@"3.,& Retinal Degenerations/Dystrophies Macular Degenerations/ Dystrophies Retinitis Pigmentosa Cone Dysfunction Syndromes ABCA4 Spectrum North Carolina Stargardt/Fundus • Achromatopsia Flavimaculatus Macular Nonsyndromic RP • Oligocone Trichromacy - Macular Dysfunction Dystrophy • Rod-cone dystrophies • Blue cone monochromacy - Peripheral Cone • Cone-rod dystrophies • Enhanced S-cone syndrome - Peripheral Rod/Cone • Cone dystrophies Isolated Foveal Hypoplasia Leber’s Congential Amaurosis BEST1 Spectrum Rod Dysfunction Syndromes • AD Best Macular Dystrophy SECORD/Juvenile RP • Congenital Stationary Night Blindness X-Linked RP • Multifocal Vitelliform Albinism X-Linked • AOFPED AR RP Complete CSNB • Oculocutaneous AD RP • AR Best Macular Dystrophy Albinism Incomplete CSNB • ADVIRC Syndromic RP Autosomal Dominant • Ocular Albinism Ciliopathies RHO,GNAT1, PDE6B PRPH2 Spectrum • Usher's syndrome Autosomal Recessive • Pattern Dystrophy • Bardet – Beidl Syndrome GRM6, TRPM1, LRIT1 • Central Areolar Choroidal • Joubert Syndrome Dys. • Fundus albipunctatus (RDH5) • Senior Loken Syndrome • Oguchi Disease (ARR, GRK1) EFEMP1 Spectrum • Alstrom Syndrome Dominant Drusen Mitochondrial (Kearns-Sayre) X-linked Retinoschisis Doyne’s Honeycomb Peroxisomal (Zellweger, Refsum) Dystrophy Choroidal Degenerations Fleck Dystrophies Malattia Levintenese Choroderemia • Benign Familial Fleck Gyrate Atrophy Sorsby Macular Dystrophy • Retinitis Punctata Albescens Bietti Crystalline Dystrophy • Alport Occult Macular Dystrophy Late Onset Retinal Dystrophy A@%46)@&%,@&?.@"G)@&C"6(&4);?"55".,&.7&8%;-&B),,)5"/&80/&B(0& The Spectrum of Retinal Degenerations RP !"#$%&'(")$*+ /$"$0*+ •+ A0/&A2/&H!/&8"6.+(.,@;"%#& •& !"#$%& •& '()*%& 1-$+.2+3"0$'*+ •& +#,& •&I&J&$)%;&K&!<A& •& '+'#$& •&JFL&$)%;5&K&'M<120& •& +'-+& •&LFJN&$)%;5&K&H!2B& •&+')*.& •&ONFPN&$)%;5&K&A2&.;&A0&2B& •&Q&LL&$)%;5&F&A>6."??>,)& :5";%.<&)*+ 4(5$%*+ •&:5();&'$,@;.?)& •&R"6;).;)3,%#& •&S%;@)6F S)"@#& •&2)3,%#& •& T.>D);6&'$,@;.?)& •&2BM& •&'),".;F !.-),& •& <(.;".;)3,%#& •& 2)75>?& •&<(.;."@& •& A#56;.?& ,$-&."*+ •&8%+>#%& •& B);"+),6;%#& 3%-("$99$0*+ •&B.56);".;&B.#)& •&!$5.5.?)5& •&8"@F4);"4();$& •&B);.U"5.?)5& •&<.,+),6;"+& •&8"6.+(.,@;"%& •&B%,&2)3,%& •&<"#">?& 67")8."(9+4.00*+ •&<),6;".#)&&&&&&& •&2.@F<.,)&@$56;.4($& •&<.,)F2.@&0$56;.4($& •&<.,)&0$56;.4($& 2)4;.@>+)@&C"6(&4);?"55".,&.7&8%;-&B),,)5"/&80/&B(0& & How do we evaluate hereditary retinal diseases? • M2V& • 1<W& • R"5>%#&G)#@& • A>6.X>.;)5+),+)& • Y#>.;)5+)",&%,9".9;%?& • <.#.;&4(.6.5& • Y%?"#$&("56.;$& Electroretinogram • M#)+6;"+%#&4.6),3%#&9),);%6)@&D$&6()&;)3,%&",&;)54.,5)&6.&%&+(%,9)&",& "##>?",%3.,E& • 2)54.,5)&6.&X%5(&"5&%&5>??)@&%+3*"6$&.7&%##&;)3,%#&+)##5&%,@&+.,5"565& .7&.*);#%44",9&4.5"3*)&%,@&,)9%3*)&+.?4.,),6&4.6),3%#5&6(%6& .;"9",%6)&7;.?&@"Z);),6&56%9)5&.7&;)3,%#&4;.+)55",9& ERG equipment Multifocal ERG Visual field Fundus photography and autofluorescence OCT FA Color testing Family history taking • 0"@&%,$.,)&",&$.>;&7%?"#$&[D#..@&;)#%3*)5\&(%*)&*"5".,&4;.D#)?5&%6& $.>,9&%9)]& • 16();&6(%,&+%6%;%+65&%,@^.;&&,))@",9&9#%55)5]& Macular degenerations and dystrophies: pitfalls and close calls Differentiating AMD from Macular dystrophies • _.&4%6(.9,.?.,"+&+#","+%#&+(%;%+6);"53+5&7.;&A80& • S;.%@&4(),.6$4"+&54)+6;>?&.7&A80&%++.>,65&7.;&.*);#%4&C"6(& @$56;.4(")5& • Y#)+-5`0;>5),& • <(.;".;)3,%#&%6;.4($`V).9;%4("+&%6;.4($& • <_R& • 0"Z);),3%3.,&"5&"?4.;6%,6&D)+%>5)&.7&"?4#"+%3.,5&7.;&6()&4;.9,.5"5/& 9),)3+&+.>,5)##",9&%,@&4;)*),6%3*)&6();%4$& A word about Drusen and Drusen-like lesions =%70$"+ 69$)>0+ ?&'$99&2.%<+9$0&."0+ • Y.+%#&@)4.5"65&.7&)U6;%+)##>#%;& • e,&6()&@))4);&;)3,%#&#%$);5&",& • 2.>,@/&$)##.C"5(&#)5".,&6(%6& @)D;"5& 4.56);".;&4.#)& #..-5&#"-)&%,&)99&$.#-& • S)6C)),&D%5%#&#%?",%&.7&2BM& • R%;"%D#)&",&5"b)/&5(%4)&%,@& • e,6),5)&($4);%>6.YA& %,@&S;>+(a5&?)?D;%,)& @"56;"D>3.,& • =$4.X>.;)5+),+)&.,&YA& • <%;D.($@;%6)5/&b",+&%,@&%6&#)%56& • <%,&D)&",6);+.,,)+6)@&",&?"@F • A++>?>#%3.,&.7&($4);;)X)+3*)& JOc&4;.6)",5& 4);"4();$&6.&7.;?&;)3+>#%;& ?%6);"%#&D)6C)),&&6()& • Y>,@.5+.4$d&$)##.C"5(&,.@>#%;& 4%f);,& ,)>;.;)3,%&%,@&2BM& #)5".,&#.+%6)@&%6&6()&4.56);".;& 4.#)& • <>3+>#%;& • 2)3+>#%;& • <.##."@& Patient # 1 • gP&$E.E&?%#)&4;)5),65&7.;&)*%#>%3.,&.7&'6%;9%;@6&8%+>#%;&0$56;.4($&& • _.&*"5>%#&+.?4#%",65&& • B8=d&:#+);%3*)&+.#"35&5^4&+.#)+6.?$/&()%@%+()5/&%,)?"%/&,#&@")6& • Y1=Ud&[email protected])@& • 21'd&_)9%3*)& Exam ,&-#'+$5$++ 4$@+$5$+ ?&07(9+()7&'5++ ON^ON& ON^ON& !3A+ JP& JO& B,,+ h^h& h^h& 1"'$%&.%+0$-<$"'++ _.;?%#& _.;?%#& 1"'$%&.%+C&'%$.70+ _.&+)##& _.&+)##& Pattern dystrophy-PRPH2 • A0& • B;)5),6&",&?"@#"7)&C"6(&?"#@&+),6;%#&*"5".,& @"56>;D%,+)5& • S>f);X$& • 2)3+>#%;& • Y>,@>5&4>#*);>#),6>5& • B5)>@.F'6%;9%;@6& • Y#)+-5&",&6()&4.56);".;&4.#)&%,@&%;.>,@&*%5+>#%;& %;+%@)5& • B;)+)@)@&D$&?%+>#%;&4%f);,&@$56;.4($&.;& ,.,54)+"G+&7.*)%#&+(%,9)5& • YAY&5(.C5&("9(#$&",+;)%5)@&%>6.YA/&C("+(&)*.#*)& 6.C%;@&+.,X>),6&%6;.4("+&%;)%5&%,@&5(.C5&#%;9);& b.,)&.7&@)+;)%5)@&YAY&5"9,%#& Pattern vs AMD • <.,7>5".,&D)+%>5)& • <#","+%##$&*"5"D#)&5"9,5&4;)5),3,9&",&?"@#"7)&%,@&*"5>%#&+.?4#%",5&?%$&?%,"7)56& #%6);&& • ')+.,@%;$&+(%,9)5&5>+(&%5&<_R&.;&VA& • Y)%6>;)5&6(%6&()#4&@"Z);),3%6)& • 2)#%3*)#$&)%;#$&%9)& • B.5"3*)&7%?"#$&(U& • 8.;)&4;.,.>,+)@&%>6.YA& • B);"4();%#&;)3,%#&%D,.;?%#"3)5&C"6(&+.;;)54.,@",9&%D,.;?%#"3)5&ZM2V& • V),)3+&6)53,9& Patient # 2 • gi&$E.E&7)?%#)&4;)5),65&7.;&)*%#>%3.,&.7&'6%;9%;@6&8%+>#%;& 0$56;.4($&& • _.&*"5>%#&+.?4#%",65/&)U+)46&5()&@.)5&,.6&#"-)&6.&@;"*)&%6&,"9(6& • B8=d&_)9%3*)& • Y1=Ud&_)9%3*)& • 21'd&_)9%3*)& Exam ,&-#'+$5$++ 4$@+$5$+ ?&07(9+()7&'5++ ON^OL& ON^gN& !3A+ Jg& JO& B,,+ h^h& h^h& 1"'$%&.%+0$-<$"'++ B.56);".;&4.#%;&+%6%;%+6& B.56);".;&4.#%;&+%6%;%+6& 1"'$%&.%+C&'%$.70+ _.&+)##& _.&+)##& Stargardt disease—ABCA4 • A2& • Y";56&O&@)+%@)5&.7&#"7)& • B;.9;)55"*)&+),6;%#&*"5".,&#.55& • YAYd&$)##.C&X)+-&+.;;)54.,@&6.&",6),5)& %>6.YA/&5.?)&X)+-5&5>;;.>,@)@&D$&(%#.&.7& ($4.%>6.YA& • 0%;-&+(.;."@&",&iNj& • 1<W&5(.C5&($4);;)X)+3*)&6("+-),",9&.7&2BM& AMD vs Stargardt • <.,7>5".,&D)+%>5)&.7&& • !%6)&%9)&.7&.,5)6& • W()&4;)5),+)&.7&$)##.C&X)+-5/&+(.;".;)3,%#&%6;.4($&%,@&;%;)#$&<_R8& • Y)%6>;)5&6(%6&()#4&@"Z);),3%6)& • Y#)+-5&%;)&?.;)&";;)9>#%;#$&5(%4)@&6(%,&@;>5),& • e,6),5)&%>6.YA&C"6(&5>;;.>,@",9&(%#.&.7&@)+;)%5)@&AY& • 0%;-&+(.;."@& • 8>6%3.,&",&AS<AP&& Patient # 3 • hg&$E.E&7)?%#)&;)7);;)@&7.;&kX>"@l&",&6()&#)m&)$)& • _.3+)5&@)+#",)&",&RA&10& • B8=d&_.,+.,6;"D>6.;$& • B1=Ud&k,.&@"5)%5)&+%>5",9&*%;"%3.,5&",&20'l& Exam ,&-#'+$5$++ 4$@+$5$+ ?&07(9+()7&'5++ ON^iN& ON^PN& !3A+ JJ& JJ& B,,+ _^A& _^A& 1"'$%&.%+0$-<$"'++ _.;?%#& _.;?%#& 1"'$%&.%+C&'%$.70+ _.&+)##& _.&+)##& AOFPED • 1,)&.7&6()&4%f);,&@$56;.4(")5& • 8"#@&&RA&#.55&.;&?)6%?.;4(.45"%& • S"#%6);%#&5?%##&;.>,@&$)##.CFC("6)&#)5".,5&",&6()& 7.*)%&C"6(.>6&@;>5),& • YAYd&($4);AY& • YAd&0.6F%,@F=%#.&.;&k5.#%;&)+#"45)l&& • 1<W&#)5".,5&D)6C)),&,)>;.;)3,%&%,@&2BM/& %@*%,+)@&@"5)%5)&&4(.6.;)+)46.;5&%,@&2BM& D)+.?)&@"5;>46)@& • _.;?%#&.;&?"#@#$&%D,.;?%#&M1V& • V),)3+&+%>5)&",&?",.;"6$&.7&465& AOFPED vs AMD • <.,7>5".,&D)+%>5)&.7& • '?%##&;.>,@&$)##.C&C("6)&?%+>#%;&#)5".,&6(%6&?%$&D)&+.?4#"+%6)@&D$&<_R& • Y)%6>;)5&6(%6&()#4&@"Z);),3%3.,d& • R"6)##"7.;?&#)5".,&C"6(.>6&@;>5),& • 8%;-)@&%>6.YA& • !)5".,&+.;;)54.,@",9&6.&($4);;)X)+3*)&%++>?>#%3.,&%D.*)&6()&2BM& Take home points: • Y>,@.5+.4$/&%>6.YA/&1<W&%,@&)#)+6;.4($5".#.9$&%;)&)55),3%#&",& %44;.%+(",9&4%3),65&C"6(&?%+>#%;&@$56;.4(")5& • ="56.;$&6%-",9d& • '4)+"G+&5$?46.?5& • Y%?"#$&("56.;$& & Take home points: • Y>,@.5+.4$/&%>6.YA/&1<W&%,@&)#)+6;.4($5".#.9$&%;)&)55),3%#&",& %44;.%+(",9&4%3),65&C"6(&?%+>#%;&@$56;.4(")5& • ="56.;$&6%-",9d& • '4)+"G+&5$?46.?5& • Y%?"#$&("56.;$& & Fundus autofluorescence • W()&?.56&*%#>%D#)&@"Z);),3%3,9&6..#&6.&@"53,9>"5(&&@$56;.4(")5&7;.?& )%+(&.6();&%,@&7;.?&A80& • e,@";)+6&;)X)+3.,&.7&?)6%D.#"+&+(%,9)5&%,@&#"4.7>5+",&%++>?>#%3.,& %6&6()&#)*)#&.7&6()&2BM& Optical Coherence Tomography • '0F1<W&%##.C5&("9(F;)5.#>3.,&%,%#$5"5&.7&6()&%,%6.?"+%#&#.+%3.,&.7& 6()&@)4.5"65&%,@^.;&X)+-5&",&&.;&>,@);&6()&;)3,%&.;&B2M& Psychophysical and electrophysiological testing • ?7M2V&+%,&D)+.?)&%D,.;?%#&)%;#$&",&6()&+.>;5)&.7&6()&@"5)%5)& • !"?"6)@&*%#>)&",&@"Z);),3%#&@"%9,.5"5& • ZM2V&+%,&D)+.?)&4;.9;)55"*)#$&%D,.;?%#&",&5.?)&@"5)%5)5&C"6(&3?)& • M1V&;)X)+65&4%,;)3,%#&7>,+3.,&.7&2BM& Genetic testing • A80&"5&?>#37%+6.;"%#&@"5)%5)&C"6(&5)*);%#&9),)3+&%,@&),*";.,?),6%#& 7%+6.;5& • S)C%;)&.7&4(),.6$4"+&()6);.9),)"6$& • M54)+"%##$&()#47>#&",&4%3),6&C"6(&)%;#$&%,@&),@F56%9)&@"5)%5)& • A"@5&",&4;.*"@",9&%&+#","+%#&4;.9,.5"5&& Genetic Testing • V),)3+&6)565&%;)&6)565&.,&D#..@&%,@&.6();&355>)&6.&G,@&9),)3+& @"5.;@);5& • Y",@",9&9),)3+&@"5)%5)5&",&>,D.;,&D%D")5& • Y",@",9&.>6&"7&4).4#)&+%;;$&%&9),)&7.;&%&@"5)%5)&%,@&?"9(6&4%55&"6&.,&6.&6()";& +("#@;),& • '+;)),",9&)?D;$.5&7.;&@"5)%5)& • W)53,9&7.;&9),)3+&@"5)%5)5&",&%@>#65&D)7.;)&6()$&+%>5)&5$?46.?5& • 8%-",9&%&@"%9,.5"5&",&%&4);5.,&C(.&(%5&@"5)%5)&5$?46.?5& • Y"9>;",9&.>6&6()&6$4)&.;&@.5)&.7&%&?)@"+",)&6(%6&"5&D)56&7.;&%&+);6%",&4);5.,& • B).4#)&(%*)&?%,$&@"Z);),6&;)%5.,5&7.;&D)",9&6)56)@&.;&,.6&D)",9&

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    71 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us